CVD AND RENAL DISEASE IN T2DM: Individualizing Therapeutic Options to Reduce Comorbid Risk

Released On
October 01, 2018

Expires On
October 01, 2019

Media Type
Internet

Completion Time
60 minutes

Specialty
Family physicians, primary care physicians, nurse practitioners/physician assistants, internal medicine

Topic(s)
Type 2 diabetes mellitus

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Boston University School of Medicine and Rockpointe.

 

This activity is supported by an independent educational grant from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly USA, LLC; and Novo Nordisk Inc..

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Physicians — maximum of 1.0 AAFP Prescribed Credits

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for family physicians, including primary care physicians and internal medicine specialists, who manage patients with T2DM.

Program Overview

Type 2 diabetes mellitus (T2DM) continues to pose a major public-health problem. This disease can be further complicated by the presence of comorbidities, specifically cardiovascular disease (CVD) and renal complications. CVD not only remains the leading cause of death in T2DM patients, the presence of cardiovascular complications reduces patient quality of life. Chronic kidney disease, often underdiagnosed until later stages of disease, also increases the risk of CVD in patients with T2DM. Reduction of cardiovascular risk through lifestyle intervention and pharmacologic therapy in patients with T2DM is critical.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Utilize evidence-based recommendations to individualize pharmacologic treatment options for patients with T2DM
  • Recognize the cardiovascular and renal benefits associated with glucose-lowering therapies in order to optimally manage patients with T2DM and associated comorbidities

Faculty

Prakash Deedwania, MD, FACC, FAHA, FACP, FASH, FHFSA, FESC

Professor of Medicine
UCSF School of Medicine
San Francisco, CA

Ellen H. Miller, MD

Professor of Science Education, Medicine, and Obstetrics and Gynecology
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Senior Medical Director
North Shore – LIJ CareConnect
East Hills, NY

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: cme@bu.edu.

American Academy of Family Physicians (AAFP) Credit

This Enduring Material activity, CVD AND RENAL DISEASE IN T2DM: Individualizing Therapeutic Options to Reduce Comorbid Risk, has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 10/1/2018. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Steering Committee

The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Prakash Deedwania, MD, FACC, FAHA, FACP, FASH, FHFSA, FESC

  • Advisor/Consultant: Janssen

Ellen H. Miller, MD

  • Nothing to Disclose

Elliot Sternthal, MD

  • Nothing to Disclose

Non-faculty Content Contributors

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Kathy Merlo; Blair St. Amand; Natalie Sanfratello; Elizabeth Drury; Brian Jack, MD: Nothing to disclose

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

Method of Participation

There is no fee for this educational activity. In order to receive credit, you must watch the webcast, pass the post-test with a score of 70% or greater, and complete the evaluation. You will have 5 opportunities to take and pass the post-test.

COURSE VIEWING REQUIREMENTS

This site is best viewed with an HTML5 compatible browser, this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the facult. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information

For information about the accreditation of this program, please email: cme@bu.edu.

Technical Support: 1-800-688-2421 Prompt '6'.